mitoxantrone has been researched along with Cardiac Rupture, Traumatic in 2 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone (MXT) is an androstenedione that is used to treat cancers and progressive forms of multiple sclerosis; however, its use is limited by its cardiotoxicity." | 3.85 | Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice. ( Bradley, J; Burn, B; Chuang, G; Coy, DH; Maderdrut, JL; Subramaniam, V; Varner, KJ; Xia, H, 2017) |
| "The aim of this study was to evaluate the plasma level changes of B-type natriuretic peptide (BNP), biochemical marker of heart failure, and echocardiographic parameters during mitoxantrone treatment in 22 multiple sclerosis (MS) patients (8 males, 14 females, mean age 37." | 3.75 | B-type natriuretic peptide as a marker of subclinical heart injury during mitoxantrone therapy in MS patients--preliminary study. ( Bartosik-Psujek, H; Jankiewicz, M; Luchowski, P; Mitosek-Szewczyk, K; Rubaj, A; Stelmasiak, Z; Szczepańska-Szerej, A; Wojczal, J, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Subramaniam, V | 1 |
| Chuang, G | 1 |
| Xia, H | 1 |
| Burn, B | 1 |
| Bradley, J | 1 |
| Maderdrut, JL | 1 |
| Coy, DH | 1 |
| Varner, KJ | 1 |
| Luchowski, P | 1 |
| Mitosek-Szewczyk, K | 1 |
| Bartosik-Psujek, H | 1 |
| Rubaj, A | 1 |
| Jankiewicz, M | 1 |
| Wojczal, J | 1 |
| Szczepańska-Szerej, A | 1 |
| Stelmasiak, Z | 1 |
2 other studies available for mitoxantrone and Cardiac Rupture, Traumatic
| Article | Year |
|---|---|
Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.
Topics: Animals; Cardiotoxicity; Cell Line, Tumor; Disease Models, Animal; Heart Injuries; Humans; Mice; Mit | 2017 |
B-type natriuretic peptide as a marker of subclinical heart injury during mitoxantrone therapy in MS patients--preliminary study.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Biomarkers; Echocardiography; Female; Heart Inju | 2009 |